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The Epstein-Barr virus (EBV) BGLF4 gene product is a protein kinase (PK). Although this kinase has been
characterized and several of its targets have been identified, its biological role remains enigmatic. We have
generated and assessed a BGLF4 knockdown phenotype by means of RNA interference and report the
following: (i) BGLF4-targeting small interfering RNA effectively inhibited the expression of its product, the
viral PK, during lytic reactivation, (ii) BGLF4 knockdown partially inhibited viral DNA replication and
expression of selected late viral genes, (iii) the absence of EBV PK resulted in retention of the viral nucleo-
capsids in the nuclei, and (iv) as a result of the nuclear retention, release of infectious virions is significantly
retarded. Our results provide evidence that EBV PK plays an important role in nuclear egress of the virus and
ultimately is crucial for lytic virus replication.
Phosphorylation/dephosphorylation is one of the most com-
mon ways to regulate the activity of proteins, and viruses often
hijack cellular kinases or encode their own, with the result that
cellular machinery is subverted into support of viral replica-
tion. All human herpesviruses encode at least one protein
kinase (PK), and these PKs can be divided into two groups,
exemplified by the alphaherpesvirus-encoded PKs. These PKs
have been suggested to play roles in viral gene expression (37),
inhibition of apoptosis (26), viral DNA synthesis and encapsi-
dation (44), and nuclear egress (24, 27, 39). The group exem-
plified by the herpes simplex virus (HSV) UL13 PK is encoded
by all herpesviruses, and its conservation across the different
herpesvirus subfamilies (alpha-, beta-, and gammaherpesvi-
ruses) (4, 41) indicates the significant role of this group of PKs
in viral replication and pathogenesis.
The Epstein-Barr virus (EBV) BGLF4 gene product, a
UL13 homologue, is a serine/threonine PK and is the only PK
identified in the EBV genome (4, 41). EBV PK has an early
expression kinetics, and its levels remain high throughout the
EBV lytic program (14). It is detected mainly in the nuclei of
EBV-infected cells (14, 43). Although only a limited number of
targets for EBV PK have been identified thus far, their variety
implies a multiplicity of processes and steps in viral replication
in which this PK is involved. The EBV PK targets identified to
date are as follows: the EBV BMRF1 gene product (5, 15), the
viral DNA polymerase processivity factor; EBNA2 (46), a key
EBV latency transcriptional regulator; the EBNA2 coactivator
EBNA-LP (19); BGLF4 itself (5, 13, 18, 19); the EBV BZLF1
gene product (1), a multifunctional protein, best known as
initiator of the EBV lytic program (22, 40); and cellular trans-
lation elongation factor 1 (18, 20). Similar to other UL13
homologues, EBV PK is a part of the tegument (1, 43), a virion
structural element whose components are thought to play sig-
nificant roles in establishing favorable conditions for viral rep-
lication. EBV PK demonstrates a reasonable functional simi-
larity to other members of the group (20, 21); however,
compounds that inhibited the enzymatic activity of human cy-
tomegalovirus (HCMV) UL97 (homologous to EBV PK) (24,
28, 29, 48) failed to inhibit EBV PK in vitro (13). Interestingly,
maribavir, an antiviral compound that inhibits replication of
both HCMV (3, 33) and EBV (47) and is thought to act
through the viral PK, failed to inhibit EBV PK as well (13).
The biological significance of EBV PK-mediated phosphory-
lation is unclear for all of its targets, and even though this
phosphorylation has been linked to reduction of transcrip-
tional activity for EBNA2 and EBNA-LP (19, 45, 46), its con-
sequences in the context of viral infection have never been
explored.
Thus, one of the major questions that remained unanswered
is that of the precise role(s) of EBV PK in the viral life cycle.
While HSV-1 UL13 and HCMV UL97 deletion mutants have
been created and their phenotypes characterized (6, 34, 35), an
EBV BGLF4 deletion mutant has not been characterized yet.
Here, we address this question by knocking down EBV BGLF4
expression by using RNA interference (RNAi) techniques dur-
ing reactivation of the viral lytic cycle. We take advantage of
293 cells that harbor recombinant EBV, which expresses a
hygromycin resistance gene and green fluorescent protein
(GFP) (7), and in which lytic infection can be easily induced by
EBV BZLF1 expression. In this system, we demonstrate that
(i) EBV PK protein expression diminished to undetectable
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levels upon expression of BGLF4-targeting small interfering
RNA (siRNA); (ii) EBV PK knockdown partially inhibited
viral DNA synthesis and expression of selected late genes; (iii)
in contrast, this knockdown greatly reduced the amount of
infectious virus released during viral lytic reactivation; and (iv)
virion release is blocked at the stage of nuclear egress, likely
through its interaction with components of the primary envel-
opment complex.
Inhibition of EBV BGLF4 expression by RNAi. In order to
generate a BGLF4 knockdown phenotype, we designed a num-
ber of siRNAs targeting different regions of BGLF4 mRNA
and screened their abilities to inhibit transient EBV PK ex-
pression in the 293 HEK cell line (data not shown). Both the
negative control (si-NC) and the BGLF4-targeting siRNAs
were cloned into pHTPsiRNA (a gift from William Reed,
University of North Carolina at Chapel Hill). Transfections
were performed using Lipofectamine 2000 (Invitrogen), fol-
lowing the manufacturer’s procedure. The best-performing
siRNA (designated si-PK) was selected for further experi-
ments. We first tested the ability of si-PK to inhibit EBV PK
expression during viral lytic reactivation. Viral lytic reactiva-
tion was achieved by transient expression of the EBV BZLF1
gene in 293/EBV cells (pSG5/BZLF1 is a gift from Shannon
Kenney, University of North Carolina at Chapel Hill). 293/
EBV (a gift from Henri-Jacques Delecluse, German Cancer
Research Center, Heidelberg, Germany) is a 293 human em-
bryonic kidney cell line harboring a recombinant EBV genome
that expresses GFP and a hygromycin resistance gene (7).
Expression of the EBV PK, EBV EA-D, and EBV BZLF1
proteins upon induction of the lytic program was analyzed by
immunoblotting (Fig. 1A). Monoclonal antibodies (MAb)
against -tubulin were purchased from Sigma (St. Louis, MO);
MAb against EA-D were purchased from Bioworld Consulting
Laboratories (Mt. Airy, MD); polyclonal EBV PK antibody
was generated and described previously (14). MAb against
p-ERK and secondary donkey anti-mouse and anti-rabbit
horseradish peroxidase-conjugated antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Preparation of the
whole-cell lysates and immunoblotting were described previ-
ously (15).
None of the viral lytic proteins was expressed in mock-
transfected cells (Fig. 1A, lane 1), whereas EBV-BZLF1 ex-
pression resulted in the appearance of both EBV PK and
EA-D proteins (Fig. 1A, lane 2). While si-NC did not signifi-
cantly affect the expression profiles of the analyzed proteins,
si-PK abolished EBV PK expression and also resulted in loss of
the hyperphosphorylated form of EA-D, a known EBV PK
target (5, 15), as shown by loss of the more slowly migrating
upper band (Fig. 1A, lanes 3 and 4). Equal levels of transfected
BZLF1 protein in all lanes in Fig. 1A suggest comparable
levels of viral reactivation in all samples. Equal levels of phos-
phorylated ERK (p44/p42) indicate that overall PK activities in
the cell remain unaffected. These data confirmed the validity of
the RNAi approach in generating a viral knockdown pheno-
type(s) by targeting respective viral genes.
EBV PK knockdown reduces infectivity of released virus.
Since EBV titers cannot be evaluated by classical plaque as-
says, there have been no established means for assessing the
final outcome of viral lytic infection. The use of recombinant
EBV that expresses GFP allows semiquantitation of viral titers
through a superinfection of susceptible cell lines (such as Raji,
a Burkitt’s lymphoma cell line latently infected with EBV [36])
and analysis of GFP expression. In application of this method,
900 l of virus-containing supernatants collected from 293/
EBV transfected cells was used to infect 2  105 Raji cells
(Fig. 1B), and after 48 to 72 h, GFP expression was analyzed by
flow cytometry. The assays demonstrated that EBV PK knock-
down resulted in significant reduction of viral titers (up to
90%) as reflected by the number of GFP-expressing Raji cells.
The results indicate that EBV PK is critical for production of
infectious virus.
Effect of EBV PK knockdown on viral DNA synthesis. EBV
PK has previously been shown to hyperphosphorylate viral
DNA polymerase processivity factor EA-D (the BMRF1 gene
FIG. 1. EBV BGLF4-targeting siRNA (si-PK) abolishes expression
of EBV PK and hyperphosphorylation of EA-D during viral lytic re-
activation and reduces EBV infectivity. (A) The viral lytic program was
induced in 293/EBV cells by the expression of EBV BZLF1 alone or
in combination with si-NC (negative control) or si-PK. Whole-cell
lysates were prepared at 48 h postinduction, subjected to sodium do-
decyl sulfate-polyacrylamide gel electrophoresis, and analyzed by im-
munoblotting. Tubulin served as a loading control. (B) Raji cells were
coincubated with the supernatants collected at 48 h posttransfection,
and the number of infected (GFP-expressing) cells was determined by
fluorescence-activated cell sorting analysis. The graph represents re-
sults from three independent experiments and shows percentages of
infected cells, normalized to negative (0%) and positive (100%) con-
trols,  standard deviations.
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product) (5, 14, 15), although the importance of this mod-
ification remains unclear. Assuming that the knockdown of
EBV PK could affect DNA viral synthesis, we have assessed
it by quantitative PCR using a TaqMan probe targeting the
EBV BamHI fragment, which has previously been described
in detail (8, 9). Briefly, total genomic DNA was isolated
from 293/EBV cells 48 h after viral reactivation using a
DNeasy tissue kit (QIAGEN). One microliter of this DNA
was analyzed by real-time PCR using an ABI 7900HT real-
time PCR system under the following cycle conditions: 50°C
for 2 min (1 cycle), 95°C for 10 min (1 cycle), and 95°C for
15 s and 60°C for 1 min (40 cycles). Viral DNA copy num-
bers were calculated from external standards of known con-
centrations of EBV B95-8 DNA (purchased from Advanced
Biotechnologies Inc., MD). The primers and the probe used





In the absence of viral lytic reactivation, 6.04  103 copies/ng
of total DNA were detected. Upon reactivation, the copy num-
bers increased about 10-fold, reaching 5.85  104 copies/ng.
Expression of si-NC resulted in a slight increase (6.76  104
copies/ng), while expression of si-PK resulted in about a 30%
decrease (4.2  104 copies/ng) in copy numbers. Thus, al-
though these results indicate that EBV DNA synthesis is af-
fected by the absence of the viral PK, a significant drop in viral
infectivity can hardly be explained by this reduction in viral
DNA synthesis. The results are summarized in Table 1.
Viral protein expression during EBV PK knockdown. Next,
we analyzed the consequences of EBV PK knockdown in the
context of viral lytic infection. Expression levels for viral pro-
teins from latent, immediate-early, early, and late classes were
evaluated by immunofluorescence (IF) and/or immunoblot-
ting. For IF, cells were fixed with 3.7% formaldehyde, followed
by permeabilization in 0.1% Triton X-100. Viral proteins were
detected by sequential incubation with respective primary an-
tibodies followed by donkey anti-mouse Alexa-594-conjugated
antibody (Molecular Probes). MAb against EA-D, gp350/220,
and viral capsid antigen (VCA) were purchased from Bioworld
Consulting Laboratories (Mt. Airy, MD); MAb against BFRF1
and BFLF2 were gifts from A. Faggioni (Università di Roma
La Sapienza, Rome, Italy). Samples were analyzed with a Zeiss
Axiovert 200 microscope with a 5 or 10 objective, and
digital images were captured with OpenLab imaging software
(Improvision) and an Axiocam cooled charge-coupled-device
camera.
Based on these assays, the tested proteins can be divided
into three groups: (i) proteins whose expression did not
change, (ii) proteins whose expression changed slightly, and
finally, (iii) proteins whose expression changed drastically dur-
ing EBV PK knockdown. The first group consists of immedi-
ate-early protein R as well as several early proteins: EA-D
(Fig. 1A and 2A) and the large (BORF2 gene product) and the
FIG. 2. Effects of EBV PK knockdown on the course of the viral
lytic program. 293/EBV cells were treated as described for Fig. 1.
(A) Expression of early (EA-D) and late (gp350 and VCA) viral
proteins was visualized by indirect IF microscopy with the respective
antibodies. GFP expression indicates the total number of EBV cells.
(B) Whole-cell lysates were subjected to sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis, and the expression of the EBV BFRF1
and BFLF2 proteins was determined by immunoblotting. PC, positive
control.
TABLE 1. Quantitation of intracellular and extracellular viral
DNA by real-time PCRa
Viral DNA
type
EBV DNA copy number for indicated treatment
Mock
treated Z si-NC si-PK
Extracellularb 7.98  102 7.67  104 7.68  104 5.48  103
Intracellularc 6.04  103 5.85  104 6.76  104 4.2  104
e/i ratiod 0.132 1.311 1.136 0.131
a Total DNA was isolated from cells and DNase-treated supernatants as de-
scribed in the text. The viral DNA was quantified in 1 l of total cellular or 4 l
of supernatant-derived DNA by real-time PCR.
b Extracellular viral DNA levels are expressed as numbers of copies per ml of
the supernatant.
c Intracellular viral DNA levels are expressed as numbers of copies per ng of
the total DNA.
d e, extracellular viral DNA; i, intracellular viral DNA.
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small (BaRF1 gene product) subunits of the viral ribonucle-
otide reductase (not shown). The second group is exemplified
by the BFRF1 protein, one of the factors involved in nuclear
egress (Fig. 2B), and the late proteins gp350/220 and VCA
(Fig. 2A). The third group includes BFLF2, another nuclear
egress factor, whose expression was almost abolished. None of
the proteins could be detected in negative controls (not shown)
or in mock-induced cells (Fig. 2B). In contrast, all of them
could be readily detected during lytic reactivation (Fig. 1A and
2A and B). These observations demonstrated a potential in-
volvement of EBV PK in the regulation of several pathways
during the viral lytic program. In addition, the abolishment of
BFLF2 expression suggests a potential role for the kinase in
nuclear egress.
EBV PK knockdown inhibits production of infectious virus
at nuclear egress. The markedly reduced capacities of super-
natants from cells in which EBV PK has been knocked down to
infect Raji cells (Fig. 1B) and the loss of BFLF2 expression
suggest that the kinase may be involved in regulation of nu-
clear egress. To examine this hypothesis, we quantitated levels
of virion-associated DNA in supernatants by real-time PCR.
For the preparation of DNA from intact virions, 100 l of the
filtered supernatants was treated with 2 l of RQ1 DNase
(Promega) for 1 h at 37°C, and reactions were stopped by the
addition of EDTA. Total DNAs were prepared from superna-
tants with a DNeasy tissue kit (QIAGEN) according to the
manufacturer’s instructions. The viral DNA was quantified by
real-time PCR as described above.
Supernatants from the mock-transfected 293/EBV cells
contained 7.98  102 copies/ml of supernatant. Viral reactiva-
tion resulted in an approximately 100-fold increase in copy
numbers, reaching 7.67  104 copies/ml for the positive control
(addition of EBV Z only) and 7.68  104 copies/ml for the
si-NC sample. In contrast, si-PK expression resulted in an
almost 15-fold drop in EBV genome copy numbers (5.48  103
copies/ml). Moreover, due to the fact that si-PK slightly inhib-
ited viral DNA replication, we calculated the ratio of extracel-
lular, DNase-resistant viral DNA to total intracellular viral
DNA and found that this ratio for the si-PK-treated group is
very close to that for the mock-treated group (0.131 and 0.132,
respectively), while during viral reactivation or si-NC treat-
ment, the ratios were significantly higher (1.311 and 1.136,
respectively) (Table 1). These data reiterate the Raji infectivity
data (Fig. 1B) and suggest EBV PK involvement in regulation
of viral nuclear egress.
Finally, we have assessed subcellular distribution of EBV
FIG. 3. EBV PK knockdown causes nuclear retention of viral capsids. The lytic program was reactivated in 293/EBV cells as described for
Fig. 1, and the cells were fixed in 2% glutaraldehyde at 48 h postreactivation. Ultrathin sections were analyzed by electron microscopy. The cells
were transfected with BZLF1 only (A) to reactivate the viral lytic program or cotransfected with si-NC (B) or si-PK (C and D). Arrows point to
capsids in the cytoplasm (B). Nu, nucleus; NM, nuclear membrane; PM, plasma membrane.
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particles in 293/EBV cells by electron microscopy. The cells
were fixed with 2% glutaraldehyde and then postfixed in 1%
osmium tetroxide in veronal acetate buffer (pH 7.4) for 1 h at
25°C, stained with 0.1% tannic acid in the same buffer for 30
min at 25°C and with uranyl acetate (5 mg/ml) for 1 h at 25°C,
dehydrated in acetone, and embedded in Epon 812. Thin sec-
tions were examined either unstained or poststained with ura-
nyl acetate and lead hydroxide, using a Morgagni 268D elec-
tron microscope (Philips Electron Optics, Eindhoven, The
Netherlands). For each transfectant, 25 sections of cells posi-
tive for the presence of nucleocapsids in the nucleus were
recorded with a charge-coupled-device camera and analyzed
with Analysis software (Soft Imaging System GmbH, Münster,
Germany). Figure 3 depicts representative samples used for
these analyses.
As shown in Table 2, expression of si-NC practically did not
change the number or the distribution of virions, whereas in
the presence of si-PK, the majority of viral particles were
detected in the nucleus, and virtually no virions were detected
in the cytoplasm. Taken together, these observations are con-
sistent with a block of viral nuclear egress with subsequent
sequestration of nucleocapsids in the nucleus.
Discussion. In this study, we have generated an EBV
BGLF4 knockdown phenotype in order to begin to understand
the biological role of the PK encoded by this gene. The results
of our analyses provide strong evidence for a role for EBV PK
in regulation of primary envelopment, a process in which a
maturing viral particle is enveloped while crossing the nuclear
membrane. This assertion is based on similarities between the
BGLF4 knockdown phenotype and a BFRF1 knockout phe-
notype reported previously (10). The BFRF1/BFLF2 complex
is homologous both positionally and most likely functionally to
the UL34/UL31 complex of the alphaherpesviruses (2, 30).
Nuclear egress and viral components involved in this process
have been best studied with alphaherpesviruses (31, 32). Com-
parison of these components among the different groups of
herpesviruses suggests a high degree of functional conservation
(2, 30). Requirement of the US3 kinase for the optimal func-
tion of the UL34/UL31 complex has been demonstrated by
several groups (17, 23, 38, 39, 42), and both components of the
complex are phosphoproteins (10, 11, 16). EBV encodes no
homologs to US3, but the EBV BGLF4, a homolog of the HSV
UL13 kinase, potentially substitutes for functions of both US3
and UL13. Lake and Hutt-Fletcher have attempted to show
the involvement of EBV PK in the distribution of the BFRF1/
BFLF2 complex but could not detect differences in the distri-
bution or phosphorylation profile of either protein (25). In
contrast, several lines of evidence, including our data, indicate
EBV PK involvement. First, HCMV UL97 PK, a homolog of
EBV PK, is required for efficient nuclear egress of HCMV (24)
although it is unclear whether UL97 is able to directly phos-
phorylate the p35/p38 complex (homologous to UL34/UL31),
or it functions indirectly and is involved in nuclear lamina
disruption through interaction with p32 (lamina-associated
protein) and phosphorylation of the lamin B receptor (27).
Second, UL13 PK may regulate distribution of the UL34/UL31
complex directly or through the phosphorylation of US3 ki-
nase, as suggested by Kato et al. based on comparison of UL13
and US3 deletion mutant phenotypes and the ability of UL13
to phosphorylate US3 in vitro (17). Finally, our preliminary
results indicate that EBV PK is able to phosphorylate at least
one component of the BFRF1/BFLF2 complex in vitro (data
not shown); effects of this phosphorylation on EBV lytic reac-
tivation are currently being evaluated. Thus, although the pre-
cise mechanism by which the EBV PK regulates nuclear egress
remains uncertain, the data clearly demonstrate for the first
time a role for this protein in the context of EBV infection. It
is important to emphasize two major limitations in our ap-
proach. First, the demonstrated effect of EBV PK knockdown
on primary envelopment does not exclude the possibility of
EBV PK involvement in other aspects of infection. For in-
stance, with this approach we could not assess the potential
contribution of the kinase to tegumentation and primary in-
fection, which may be controlled in part by the kinase as well.
Second, the 293/EBV cells used in this study represent an
attractive model system of epithelial cells susceptible to EBV
infection (7, 12); however, the observed phenotype may not be
identical in B lymphocytes.
In summary, we have shown that BGLF4 gene expression is
crucial for production of infectious EBV progeny, which makes
its product, a unique PK, a potential target for antiviral ther-
apy. Our results suggest a role for this kinase in EBV biology
as a regulator of viral nuclear egress.
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